<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36565260</PMID><DateCompleted><Year>2022</Year><Month>12</Month><Day>27</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>12</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Print">1267-8694</ISSN><JournalIssue CitedMedium="Internet"><Volume>26</Volume><Issue>6</Issue><PubDate><MedlineDate>2022 DéCembre 01</MedlineDate></PubDate></JournalIssue><Title>Virologie (Montrouge, France)</Title><ISOAbbreviation>Virologie (Montrouge)</ISOAbbreviation></Journal><ArticleTitle>[Coxsackievirus B infection and pathogenesis of type 1 diabetes].</ArticleTitle><Pagination><StartPage>415</StartPage><EndPage>430</EndPage><MedlinePgn>415-430</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1684/vir.2022.0976</ELocationID><Abstract><AbstractText>Epidemiological and experimental studies suggest that enteroviruses (EV) and particularly coxsackieviruses B (CVB) are likely to trigger or accelerate the onset of islet autoimmunity and the development of type 1 diabetes (T1D) in genetically susceptible individuals. Several mutually non-exclusive mechanisms have been proposed to explain the involvement of CVB in the pathogenesis of T1D. CVB can infect and persist in the intestine, thymic cells, monocytes/macrophages, ductal cells and pancreatic β-cells, which leads to structural or functional alterations of these cells. A chronic inflammatory response and disruption of tolerance towards β-cells due to CVB infections are able to promote the recruitment and activation of pre-existing autoreactive T-cells and the destruction of β-cells. Vaccine or therapeutic strategies to control EV infections have been developed and open perspectives for the prevention or treatment of T1D.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Nekoua</LastName><ForeName>Magloire Pandoua</ForeName><Initials>MP</Initials></Author><Author ValidYN="Y"><LastName>Mercier</LastName><ForeName>Ambroise</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Vergez</LastName><ForeName>Inès</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Morvan</LastName><ForeName>Corentin</ForeName><Initials>C</Initials></Author><Author ValidYN="Y"><LastName>Mbani</LastName><ForeName>Chaldam Jespere</ForeName><Initials>CJ</Initials></Author><Author ValidYN="Y"><LastName>Sane</LastName><ForeName>Famara</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Lobert</LastName><ForeName>Delphine</ForeName><Initials>D</Initials></Author><Author ValidYN="Y"><LastName>Engelmann</LastName><ForeName>Ilka</ForeName><Initials>I</Initials></Author><Author ValidYN="Y"><LastName>Romond</LastName><ForeName>Marie-Bénédicte</ForeName><Initials>MB</Initials></Author><Author ValidYN="Y"><LastName>Alidjinou</LastName><ForeName>Enagnon Kazali</ForeName><Initials>EK</Initials></Author><Author ValidYN="Y"><LastName>Hober</LastName><ForeName>Didier</ForeName><Initials>D</Initials></Author></AuthorList><Language>fre</Language><PublicationTypeList><PublicationType UI="D004740">English Abstract</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><VernacularTitle>Infection à coxsackievirus B et pathogenèse du diabète de type 1.</VernacularTitle></Article><MedlineJournalInfo><Country>France</Country><MedlineTA>Virologie (Montrouge)</MedlineTA><NlmUniqueID>9802575</NlmUniqueID><ISSNLinking>1267-8694</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003922" MajorTopicYN="Y">Diabetes Mellitus, Type 1</DescriptorName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004770" MajorTopicYN="Y">Enterovirus</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName><QualifierName UI="Q000502" MajorTopicYN="N">physiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004769" MajorTopicYN="Y">Enterovirus Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">antivirals</Keyword><Keyword MajorTopicYN="N">coxsackievirus B</Keyword><Keyword MajorTopicYN="N">enterovirus</Keyword><Keyword MajorTopicYN="N">type 1 diabetes</Keyword><Keyword MajorTopicYN="N">vaccines</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>12</Month><Day>24</Day><Hour>7</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>12</Month><Day>25</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>12</Month><Day>28</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36565260</ArticleId><ArticleId IdType="doi">10.1684/vir.2022.0976</ArticleId><ArticleId IdType="pii">vir.2022.0976</ArticleId></ArticleIdList></PubmedData></PubmedArticle>